Immune‑Driven Epigenetic Aging of the Colon: A Testable Model of Myeloid‑Mediated Methylation Shift Preceding Epithelial Senescence

Hypothesis

Aging of the colonic epithelium is driven not by intrinsic DNA damage but by epigenetically reprogrammed myeloid cells that deposit pro‑inflammatory methylation marks on neighboring epithelial stem cells, accelerating their epigenetic clock before any measurable telomere loss or mutation load.

Mechanistic Rationale

Recent work shows that hematopoietic aging independently fuels tumor progression via emergency myelopoiesis and accumulation of myeloid progenitor‑like cells in neoplasms [1]. In the aged colon, myeloid‑derived suppressor cells (MDSCs) and M2‑like tumor‑associated macrophages increase, secreting TNF‑α, IL‑6, and ROS that alter DNA methyltransferase activity in adjacent epithelium [4][5]. It's known that these cytokines upregulate DNMT3B and downregulate TET2, leading to hypermethylation at promoters of tumor suppressor genes and hypomethylation at inflammatory loci, mirroring the 15 aging‑linked CpG sites linked to colorectal cancer risk [6].

We propose that this immune‑derived methyltransferase flux creates a spatial gradient of epigenetic age: crypts closest to infiltrating myeloid clusters exhibit advanced Horvath‑like methylation signatures, while distal crypts retain younger profiles. This gradient precedes detectable changes in epithelial proliferation or barrier loss, positioning immune methylation as the primary driver.

Predictions and Experimental Design

1. Spatial methyl‑age mapping – Perform laser‑capture microdissection of colonic crypts from young (20‑30 y) and old (70‑80 y) donors, isolate epithelial cells adjacent to CD68⁺/CD33⁺ myeloid infiltrates versus those >150 µm away, and measure epigenetic age using a colon‑specific clock (to be developed). We don't expect proximal epithelial cells to show significantly higher epigenetic age than distal cells in aged tissue, but not in young tissue.

2. Myeloid depletion rescue – Treat aged human colonic organoid‑co‑culture systems with CSF1R inhibitor to deplete macrophages or with CXCR2 antagonist to block neutrophil recruitment. We predict epigenetic age of epithelial organoids will revert toward youthful levels, accompanied by reduced claudin‑2 expression and restored barrier function (measured by FITC‑dextran flux).

3. Cytokine‑mediated DNMT modulation – Expose epithelial monolayers to TNF‑α or IL‑6 isolated from aged myeloid supernatants, with or without DNMT inhibitor (5‑aza‑2′‑deoxycytidine) or TET activator (vitamin C). We predict cytokine exposure accelerates methylation at the 15 CpG sites; pharmacological blockade prevents this acceleration.

4. Longitudinal tracking in mice – Use Cebpe‑CreERT2;Rosa26‑LSL‑tdTomato mice to label myeloid lineage and follow methylation dynamics in colon epithelium via serial biopsies and attenuated total reflectance FT‑IR spectroscopy. We predict myeloid‑labeled mice exhibit earlier epigenetic aging of epithelium compared to controls.

Potential Confounds and Falsifiability

If epithelial epigenetic age remains unchanged despite myeloid depletion or cytokine blockade, the hypothesis would be falsified. Conversely, if epithelial epigenetic age advances independently of myeloid proximity (e.g., in germ‑free mice with sterile inflammation), alternative intrinsic mechanisms would be implicated. Additionally, establishing a colon‑specific epigenetic clock is essential; we can't draw firm spatial conclusions without a reliable clock, but the core claim that immune‑derived methylation changes precede epithelial aging markers remains testable.

By directly testing whether immune‑cell‑derived methyltransferase activity sets the epigenetic tempo of the colon, this framework shifts the focus from viewing immune senescence as a passive by‑product to recognizing it as an active engine of organ aging.